Improving treatment adherence and glycemic control with weekly insulin injection
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on September 6th, 2023
|
Daily injection of insulin is the current glycemic control strategy in patients living with diabetes; however, treatment adherence is low due to the high frequency. As a result, the effectiveness of daily insulin glargine U100 injection can be lowered. Thus, a study was conducted to assess the feasibility of an once-per-week injection of insulin icodec in controlling blood glucose level
The phase 3 clinical trial included 984 participants who had been living with diabetes for an average of 11 years. The mean glycated hemoglobin of these patients were approximately 8.5% and their fasting plasma glucose levels were around 185 mg/dL. The participants were randomly assigned to receive a subcutaneous dose containing either 70 IU of insulin icodec once per week or 10 IU of insulin glargine U100 everyday. After 52 weeks of treatment, the researchers observed that those who were given insulin icodec weekly experienced 1.35% more reduction in glycated hemoglobin level than those in the daily injection group. The rate of severe hypoglycemia was similar between the two groups, and both treatment plans were associated with little adverse event. Combining the higher effectiveness and the similar safety profile, it is possible that weekly injection of insulin can be recommended over daily administration.
The phase 3 clinical trial included 984 participants who had been living with diabetes for an average of 11 years. The mean glycated hemoglobin of these patients were approximately 8.5% and their fasting plasma glucose levels were around 185 mg/dL. The participants were randomly assigned to receive a subcutaneous dose containing either 70 IU of insulin icodec once per week or 10 IU of insulin glargine U100 everyday. After 52 weeks of treatment, the researchers observed that those who were given insulin icodec weekly experienced 1.35% more reduction in glycated hemoglobin level than those in the daily injection group. The rate of severe hypoglycemia was similar between the two groups, and both treatment plans were associated with little adverse event. Combining the higher effectiveness and the similar safety profile, it is possible that weekly injection of insulin can be recommended over daily administration.